托法替尼(托法替布)用药有什么禁忌吗?

Contraindications for the Bangladesh version of tofacitinib

1. Patients with active severe infections (including local infections) should avoid using tofacitinib. Before starting tofacitinib (tofacitinib) in patients, the risks and benefits of treatment should be considered:

Patients with chronic or recurrent infections;

People who have been exposed to tuberculosis;

With a history of serious or opportunistic infections;

People who have lived or traveled in areas with endemic tuberculosis or endemic mycoses; or have an underlying disease that makes them susceptible to infection.

2. Patients should be closely monitored for signs and symptoms of tuberculosis, including patients who test negative for latent tuberculosis infection before starting treatment. Prior to the use of tofacitinib, patients with latent tuberculosis should receive standard antimycobacterial therapy. 3. It should be used with caution in patients with a possible increased risk of gastrointestinal perforation.

4. Avoid using live vaccines at the same time as tofacitinib (tofacitinib). The interval between live vaccination and initiation of tofacitinib therapy should be consistent with current vaccination guidelines for immunosuppressants.

5. Patients are advised not to breastfeed during treatment and for at least 18 hours after the last dose of tofacitinib (tofacitinib) or within 36 hours after the last dose (approximately 6 elimination half-lives).

6. Use by pregnant women can cause fetal malformations and is not recommended.

7. Tofacitinib (tofacitinib) is not recommended for patients with severe liver damage.

Efficacy of Tofacitinib

Tofacitinib is a Janus kinase (JAK) inhibitor. JAK is an intracellular enzyme that transmits signals generated by cytokine or growth factor receptor reactions on the cell membrane, affecting cellular processes, hematopoietic and immune cell functions. Tofacitinib modulates the JAK signaling pathway and eliminates STAT phosphorylation and activation. Tofacitinib (tofacitinib) can be used in patients with psoriasis and patients with moderately to severely active rheumatoid arthritis who cannot tolerate methotrexate or have poor response to methotrexate.

Instructions for taking tofacitinib

Before taking this medicine, if the patient has ever had the following conditions, please tell your doctor:

1. Liver disease (especially hepatitis B or C);

2. Heart problems (especially 50 years old)

3. Lung disease;

4. Blood clots;

5. Chronic infection;

Tofacitinib drug interactions

1. Drug therapy: Tofacitinib exposure is increased when tofacitinib is coadministered with strong inhibitors of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole) and CYP2C19 (e.g., fluconazole). It is not recommended to use tofacitinib (tofacitinib) with biologic DMARDs or strong immunosuppressives (such as azathioprine and cyclosporine).

2. Taking with food and other drugs: Avoid taking tofacitinib with grapefruit juice, and completely avoid drinking grapefruit juice during tofacitinib (tofacitinib) treatment.

3. Overdose: There is no specific antidote for overdose of tofacitinib (tofacitinib) 11 mg. In the event of overdose, advise patients to monitor for signs and symptoms of adverse reactions. For more details about medication, please click: read this article.

Recommended hot articles: